Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Purchases $24,903.87 in Stock

VolitionRx Limited (NYSE:VNRX) insider Jacob Vincent Micallef bought 43,691 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $24,903.87. Following the completion of the transaction, the insider now owns 394,352 shares in the company, valued at approximately $224,780.64. This trade represents a 12.46 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.61 on Friday. The company’s fifty day moving average is $0.69 and its two-hundred day moving average is $0.67. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.23.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. StockNews.com initiated coverage on shares of VolitionRx in a research report on Friday, December 6th. They set a “sell” rating on the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. Finally, D. Boral Capital restated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Tuesday.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC increased its position in VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.